ISA Pharmaceuticals B.V.

The combination of ISA101b and Libtayo® shows promising results in patients whose head and neck cancer progressed on anti-PD1 therapy

by

Early data presented at ASCO annual meeting 2023 shows encouraging responses to treatment in a very difficult to treat patient population Dr. Anthony Kong (Guy’s and St Thomas’ Hospitals, London), Principal Investigator, presented data from ProcemISA, an ongoing clinical trial in anti-PD1 resistant advanced HPV16+ head and neck cancer OEGSTGEEST, The Netherlands, June 6, 2023 /PRNewswire/ … Read more

ISA Pharmaceuticals to Present First Clinical Trial Data from the Phase II Study of ISA101b and Libtayo® (cemiplimab) Combination in Head and Neck Cancer at the ASCO Annual Meeting 2023

by

– Dr. Anthony Kong (Guy’s and St Thomas’ Hospitals, London), Principal Investigator, will present data from ProcemISA, an ongoing clinical trial in anti-PD1 resistant advanced head and neck cancer – This study is part of an extensive clinical development programme in HPV16 induced cancers OEGSTGEEST, Netherlands, May 25, 2023 /PRNewswire/ — ISA Pharmaceuticals B.V., a … Read more